Novabay Pharmaceuticals (NBY) Registration Filing summary

Company overview and business model

• Transitioning from eyecare and wound care products to a new business model after divesting all operational product lines in January 2025.

• Currently evaluating new opportunities and potential strategic transactions.

Financial performance and metrics

• Revenue from continuing operations for the year ended December 31, 2024, was approximately $9.7 million, primarily from eyecare product sales before divestiture.

• Wound care product revenue decreased compared to 2023.

• As of October 1, 2025, the aggregate market value of outstanding common stock held by non-affiliates is approximately $25.3 million, based on 6,010,749 shares at $4.22 per share.

Use of proceeds and capital allocation

• Net proceeds from securities sales are intended for working capital and general corporate purposes, including sales and marketing, R&D, and general and administrative expenses.